Abstract
The development and approval of anti-VEGF drugs for intravitreal injection has transformed the treatment and prognosis of several ocular conditions, including age-related macular degeneration and retinal vascular occlusion (the subject of this article). Their role in the treatment of ocular conditions is likely to continue to expand owing to the common pathway that VEGF plays in multiple retinal disorders. While important strides have been made, an important treatment challenge is the dosing frequency and the burden that this places on the patient and healthcare providers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
